GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satsuma Pharmaceuticals Inc (NAS:STSA) » Definitions » EPS without NRI

Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) EPS without NRI : $-2.01 (TTM As of Mar. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Satsuma Pharmaceuticals EPS without NRI?

Satsuma Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2023 was $-0.31. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2023 was $-2.01.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 23.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Satsuma Pharmaceuticals's EPS without NRI or its related term are showing as below:

STSA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.7   Med: 2   Max: 23
Current: 23

During the past 6 years, Satsuma Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 23.00% per year. The lowest was -27.70% per year. And the median was 2.00% per year.

STSA's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 4.7 vs STSA: 23.00

Satsuma Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2023 was $-0.31. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-2.01.

Satsuma Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2023 was $-0.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2023 was $-2.01.


Satsuma Pharmaceuticals EPS without NRI Historical Data

The historical data trend for Satsuma Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satsuma Pharmaceuticals EPS without NRI Chart

Satsuma Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS without NRI
Get a 7-Day Free Trial -1.86 -4.80 -2.73 -1.75 -2.19

Satsuma Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.49 -0.52 -0.48 -0.70 -0.31

Competitive Comparison of Satsuma Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, Satsuma Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Satsuma Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Satsuma Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Satsuma Pharmaceuticals's PE Ratio without NRI falls into.



Satsuma Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Satsuma Pharmaceuticals  (NAS:STSA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Satsuma Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of Satsuma Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
400 Oyster Point Boulevard, Suite 221, South San Francisco, CA, USA, 94080
Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.
Executives
Mutya Harsch director C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Shin Nippon Biomedical Laboratories, Ltd. 10 percent owner 2438 MIYANOURA-MACHI, KAGOSHIMA CITY, KAGOSHIMA M0 891-1394
Thomas P Soloway director C/O AUDENTES THERAPEUTICS, INC., 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Ken Takanashi director, 10 percent owner C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Commodore Capital Lp 10 percent owner 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Detlef Albrecht officer: Chief Medical Officer SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080
Thomas P. O'neil officer: Chief Financial Officer SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080
Rajeev M. Shah director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Tpg Group Holdings (sbs) Advisors, Inc. 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Heath Lukatch director 326 BOLLAY DRIVE, GOLETA CA 93117
John A Kollins director, officer: President and CEO SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080

Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) Headlines

From GuruFocus

SNBL to Acquire Satsuma Pharmaceuticals

By GlobeNewswire GlobeNewswire 04-17-2023